Recent Updates
Recently added Catalysts
AKBA Positive Sentiment Score: 70/100

Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference

Wednesday, August 6, 2025 1 min read
Key Takeaway: Akebia Therapeutics, a biopharmaceutical company focusing on kidney disease, announced that its CEO, John P. Butler, will speak at Canaccord Genuity's 45th Annual Growth Conference on August 13, 2025. The event is scheduled to occur from August 12-14 in Boston. Interested parties can access a webcast of the presentation via the company's website following the conference. This participation emphasizes Akebia's dedication to improving the lives of individuals affected by kidney disease.

Market Sentiment Analysis

POSITIVE FACTORS

  • CEO John P. Butler is participating in a notable conference.
  • The event highlights Akebia's commitment to kidney disease.
  • The conference provides an opportunity for investor engagement.

Full Press Release Details

CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will participate in a Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on Wednesday, August 13 at 1:30 PM EDT. The conference will take place August 12-14, 2025 in Boston.
A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
mcarrasco@akebia.com

Frequently Asked Questions

Who will represent Akebia at the Canaccord conference?

John P. Butler, the CEO of Akebia, will participate in the conference.

When is the Canaccord Genuity Growth Conference?

The conference takes place from August 12-14, 2025.

How can I access the webcast of Akebia's presentation?

The webcast is available in the 'Investors' section on Akebia's website.

What is the focus of Akebia Therapeutics?

Akebia Therapeutics aims to improve the lives of those affected by kidney disease.

Where is Akebia Therapeutics headquartered?

Akebia is headquartered in Cambridge, Massachusetts.

Tags: AKBA Viatris Investor Conferences Healthcare kidney disease biopharmaceutical Canaccord Genuity Boston
Last updated: Aug 6, 2025